JP2014501492A5 - - Google Patents

Download PDF

Info

Publication number
JP2014501492A5
JP2014501492A5 JP2013532277A JP2013532277A JP2014501492A5 JP 2014501492 A5 JP2014501492 A5 JP 2014501492A5 JP 2013532277 A JP2013532277 A JP 2013532277A JP 2013532277 A JP2013532277 A JP 2013532277A JP 2014501492 A5 JP2014501492 A5 JP 2014501492A5
Authority
JP
Japan
Prior art keywords
short rna
strand
rna
short
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013532277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014501492A (ja
JP5681955B2 (ja
Filing date
Publication date
Priority claimed from GBGB1016989.4A external-priority patent/GB201016989D0/en
Priority claimed from GBGB1103745.4A external-priority patent/GB201103745D0/en
Application filed filed Critical
Priority claimed from PCT/GB2011/051940 external-priority patent/WO2012046084A2/en
Publication of JP2014501492A publication Critical patent/JP2014501492A/ja
Publication of JP2014501492A5 publication Critical patent/JP2014501492A5/ja
Application granted granted Critical
Publication of JP5681955B2 publication Critical patent/JP5681955B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013532277A 2010-10-08 2011-10-10 短いｒｎａ分子 Expired - Fee Related JP5681955B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1016989.4 2010-10-08
GBGB1016989.4A GB201016989D0 (en) 2010-10-08 2010-10-08 Cell induction
GBGB1103745.4A GB201103745D0 (en) 2011-03-07 2011-03-07 Cell induction
GB1103745.4 2011-03-07
PCT/GB2011/051940 WO2012046084A2 (en) 2010-10-08 2011-10-10 Short rna molecules

Publications (3)

Publication Number Publication Date
JP2014501492A JP2014501492A (ja) 2014-01-23
JP2014501492A5 true JP2014501492A5 (https=) 2014-11-13
JP5681955B2 JP5681955B2 (ja) 2015-03-11

Family

ID=44860439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013532277A Expired - Fee Related JP5681955B2 (ja) 2010-10-08 2011-10-10 短いｒｎａ分子

Country Status (8)

Country Link
US (6) US8835400B2 (https=)
EP (2) EP2625273B1 (https=)
JP (1) JP5681955B2 (https=)
KR (1) KR20130132795A (https=)
CN (1) CN103314108B (https=)
AU (1) AU2011311344B2 (https=)
CA (1) CA2817191A1 (https=)
WO (2) WO2012046085A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012046085A2 (en) * 2010-10-08 2012-04-12 Mina Therapeutics Limited Methods of inducing insulin production
CA3012929C (en) 2012-07-31 2023-01-17 The Board Of Regents Of The University Of Texas System Methods and compositions for in vivo induction of pancreatic beta cell formation
SI3071696T1 (sl) 2013-11-22 2019-11-29 Mina Therapeutics Ltd C/EBP alfa kratko delujoči RNA sestavki in postopki uporabe
US20170044540A1 (en) * 2014-04-22 2017-02-16 Mina Therapeutics Limited Sarna compositions and methods of use
US20180305689A1 (en) * 2015-04-22 2018-10-25 Mina Therapeutics Limited Sarna compositions and methods of use
CN106480028B (zh) * 2016-10-12 2019-04-05 上海市第七人民医院 TPO基因的saRNA分子及其应用
MX2019014578A (es) * 2017-06-21 2020-12-01 Timothy A Bertram Celulas renales bioactivas inmunoprivilegiadas para el tratamiento de enfermedad renal.
KR102007457B1 (ko) 2017-06-30 2019-08-05 동국대학교 산학협력단 Cas9 단백질, 가이드 RNA 및 양친매성 펩타이드를 포함하는 나노복합체 및 이의 용도
KR20200068647A (ko) * 2017-08-11 2020-06-15 시티 오브 호프 트랜스페린 수용체 (TfR)에 대한 RNA 앱타머
US20200208152A1 (en) 2017-09-08 2020-07-02 Mina Therapeutics Limited Stabilized sarna compositions and methods of use
WO2019048632A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited STABILIZED COMPOSITIONS OF SMALL ACTIVATORY RNA (PARNA) OF HNF4A AND METHODS OF USE
US20210332366A1 (en) * 2018-04-10 2021-10-28 Ractigen Therapeutics Novel Small Activating RNA
US11584935B2 (en) * 2018-05-08 2023-02-21 University Of Miami Materials and methods for the delivery of therapeutic nucleic acids to tissues
US20210254069A1 (en) 2018-06-15 2021-08-19 Mina Therapeutics Limited Combination therapies comprising c/ebp alpha sarna
CN111849968A (zh) 2019-04-30 2020-10-30 中美瑞康核酸技术(南通)研究院有限公司 寡核苷酸分子及其在急性间歇性卟啉症治疗中的应用
US20220281911A1 (en) 2019-08-19 2022-09-08 Mina Therapeutics Limited Oligonucleotide conjugate compositions and methods of use
EP4329777A1 (en) 2021-04-28 2024-03-06 MiNA Therapeutics Limited Combination therapies comprising c/ebp alpha sarna

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US8193330B2 (en) 1999-04-06 2012-06-05 The Regents Of The University Of California Polynucleotides comprising Neurogenin3 promoter and bHLH encoding domains
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
GB0329449D0 (en) 2003-12-19 2004-01-28 Omnicyte Ltd Stem cells
EP1871426B1 (en) 2005-04-15 2017-06-07 The Regents of The University of California Small activating rna molecules and their use
US8357666B2 (en) 2005-08-01 2013-01-22 Nupotential, Inc. Reprogramming a cell by inducing a pluripotent gene through RNA interference
WO2007086990A2 (en) 2005-11-17 2007-08-02 Board Of Regents, The University Of Texas System Modulation of gene expression by oligomers targeted to chromosomal dna
JP5713377B2 (ja) 2005-12-28 2015-05-07 ザ スクリプス リサーチ インスティテュート 薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物
WO2008109556A1 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting telomerase gene expression and uses thereof
CA2679347A1 (en) 2007-03-02 2008-09-12 Mdrna Inc. Nucleic acid compounds for inhibiting bcl2 gene expression and uses thereof
BRPI0810949A2 (pt) 2007-05-29 2015-10-27 Christopher B Reid "método de preparação de células multipotentes, auto-renovadoras, diferenciadoras ou resistentes a doenças, célula e vetor pra uso do método"
AU2008308499A1 (en) * 2007-10-04 2009-04-09 Board Of Regents, The University Of Texas System Modulating gene expression with agRNA and gapmers targeting antisense transcripts
WO2009086428A2 (en) 2007-12-28 2009-07-09 The Regents Of The University Of California Methods and compositions for increasing gene expression
KR20110019727A (ko) 2008-04-07 2011-02-28 뉴포텐셜, 인크. Ｒｎａ 간섭을 통한 다능 유전자의 유도에 의한 세포 재프로그래밍
WO2009126927A2 (en) 2008-04-11 2009-10-15 Joslin Diabetes Center, Inc. Methods of generating insulin-producing cells
CN102264898B (zh) 2008-10-23 2013-10-16 国立大学法人东京大学 微小rna的功能抑制方法
AU2009313875B2 (en) 2008-11-13 2013-01-10 Baylor Research Institute Regeneration of pancreatic islets and reversal of diabetes by islet transcription factor genes delivered in vivo
WO2010108126A2 (en) * 2009-03-19 2010-09-23 Fate Therapeutics, Inc. Reprogramming compositions and methods of using the same
DK2432881T3 (en) 2009-05-18 2018-02-26 Curna Inc TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
US8785184B2 (en) 2009-07-20 2014-07-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
KR101853509B1 (ko) * 2010-01-06 2018-04-30 큐알엔에이, 인크. 췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료
GB201010557D0 (en) 2010-06-23 2010-08-11 Mina Therapeutics Ltd RNA molecules and uses thereof
US8635602B2 (en) 2010-07-26 2014-01-21 International Business Machines Corporation Verification of information-flow downgraders
WO2012046085A2 (en) * 2010-10-08 2012-04-12 Mina Therapeutics Limited Methods of inducing insulin production

Similar Documents

Publication Publication Date Title
JP2014501492A5 (https=)
MX359548B (es) Agentes de iarn modificados.
MX2020011807A (es) Composiciones y metodos para inhibir la expresion genica del virus de hepatitis b.
WO2014022739A3 (en) Modified rnai agents
MX359989B (es) Fármacos antivirales para el tratamiento de la infección por arenavirus.
MX2013005110A (es) Inhibidores del ibat para el tratamiento de padecimientos metabolicos y condiciones relacionadas.
EA200870366A1 (ru) Короткая внутренне сегментированная интерферирующая рнк
JP2012041342A5 (https=)
EA200802247A1 (ru) Схема дозирования кладрибина для лечения рассеянного склероза
BR112012018116A2 (pt) "hormônios do crescimento com eficácia in vivo prolongada"
JP2014500249A5 (https=)
JP2015514778A5 (https=)
JP2013503110A5 (https=)
UY32444A (es) Composiciones y procedimientos para terapia extendida con aminopiridinas
WO2011038933A3 (en) Anti-hsv antibody
MY143269A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
BR112014002173A2 (pt) proteínas purificadas
GB2497453A (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
PH12014502802B1 (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
MX2011012384A (es) Derivados nitrilo y sus usos y composiciones farmaceuticas.
MX348555B (es) Agente preventivo o terapeutico contra la fibrosis.
SG143203A1 (en) Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome
EA201290485A1 (ru) Производные бензамида
UA104484C2 (uk) Противірусна сполука множинної дії, її склад та спосіб лікування вірусних захворювань
EP3178498A3 (en) Composition for treating cancer associated with hpv infection